Each of the breakthrough brings life-changing hope for patients.
Pfizer is committed to developing innovative drugs to meet the unmet needs of patients and make the impossible possible.
Pfizer China R&D Center (CRDC) is an important R&D hub of Pfizer in the world and the Asia Pacific region. It provides comprehensive support services for the development projects of the global product line. Over the past more than 30 years, Pfizer has introduced over 70 innovative products to China, including original drugs and vaccines. By 2025, Pfizer plans to achieve 24 breakthrough innovative products to apply for listing, and with the gradual implementation of the strategic goal of "80%&80%, we will try our best to realize the simultaneous application of product research and development in China to meet the health needs of Chinese patients at all stages of life.
China Research & Development Center
Pfizer China R&D Center was established on October 31, 2005, at Shanghai Zhangjiang High-tech Park Zone. It is one of the earliest and largest R & D centers set up by multinational pharmaceutical enterprises in China.
In 2010, Pfizer China R&D center Wuhan Branch was established, located in Wuhan Biolake Science and Technology Industrial Park.